-
2024
-
Sep 18, 2024
PCI Biotech is recruiting a new Senior Scientist position
Sep 18, 2024
-
Sep 2, 2024
Employee share option scheme
Sep 2, 2024
-
Aug 28, 2024
PCI Biotech first half 2024 interim results
Aug 28, 2024
-
Aug 23, 2024
Invitation to first half interim 2024 results presentation
Aug 23, 2024
-
May 24, 2024
Minutes of Annual General Meeting 2024
May 24, 2024
-
May 23, 2024
Disclosure of voting rights for Chair of the Board
May 23, 2024
-
May 3, 2024
Notice of Annual General Meeting 2024
May 3, 2024
-
Apr 26, 2024
Annual Report 2023
Apr 26, 2024
-
Feb 14, 2024
PCI Biotech second half 2023 interim report
Feb 14, 2024
-
Feb 12, 2024
Invitation to second half interim 2023 results presentation
Feb 12, 2024
-
2023
-
Oct 13, 2023
PCI Biotech initiates field testing of its proprietary technology for gene therapy manufacturing
Oct 13, 2023
-
Sep 7, 2023
European patent for mRNA delivery with fimaNAc
Sep 7, 2023
-
Sep 4, 2023
PCI Biotech: Employee share option scheme
Sep 4, 2023
-
Sep 1, 2023
Write-down of share capital registered
Sep 1, 2023
-
Aug 31, 2023
PCI Biotech first half 2023 interim results
Aug 31, 2023
-
Aug 25, 2023
Invitation to first half interim 2023 results presentation
Aug 25, 2023
-
May 25, 2023
Minutes from Annual General Meeting 2023
May 25, 2023
-
May 12, 2023
PCI Biotech interim Q1 2023 results
May 12, 2023
-
May 9, 2023
Invitation to Q1 2023 results presentation
May 9, 2023
-
May 4, 2023
Notice of Annual General Meeting 2023
May 4, 2023
-
Apr 28, 2023
PCI Biotech Holding ASA: Annual Report 2022
Apr 28, 2023
-
Feb 17, 2023
PCI Biotech interim Q4 2022 results
Feb 17, 2023
-
Feb 13, 2023
Invitation to Q4 2022 results presentation
Feb 13, 2023
-
2022
-
Nov 25, 2022
Employee share option scheme
Nov 25, 2022
-
Nov 23, 2022
PCI Biotech interim Q3 2022 results
Nov 23, 2022
-
Nov 17, 2022
Invitation to Q3 2022 results presentation
Nov 17, 2022
-
Aug 31, 2022
PCI Biotech interim first-half year 2022 results
Aug 31, 2022
-
Aug 29, 2022
PCI Biotech: Invitation to first-half year 2022 results presentation
Aug 29, 2022
-
Aug 18, 2022
PCI Biotech: Company update
Aug 18, 2022
-
May 25, 2022
Minutes from Annual General Meeting 2022
May 25, 2022
-
May 11, 2022
PCI Biotech is seeking a Financial Manager
May 11, 2022
-
May 11, 2022
PCI Biotech interim first quarter 2022 results
May 11, 2022
-
May 9, 2022
PCI Biotech to present at TIDES USA 2022
May 9, 2022
-
May 4, 2022
PCI Biotech: Invitation to Q1 2022 results presentation
May 4, 2022
-
May 4, 2022
Notice of Annual General Meeting 2022
May 4, 2022
-
Apr 28, 2022
PCI Biotech Holding ASA publishes the Annual Report 2021
Apr 28, 2022
-
Mar 28, 2022
PCI Biotech CEO resigns to assume new position
Mar 28, 2022
-
Feb 18, 2022
PCI Biotech fourth quarter and preliminary full year 2021 results
Feb 18, 2022
-
Feb 14, 2022
PCI Biotech: Invitation to Q4 2021 result presentation
Feb 14, 2022
-
Jan 24, 2022
PCI Biotech: Update on the RELEASE trial
Jan 24, 2022
-
Jan 11, 2022
PCI Biotech: Publication of preclinical tuberculosis results
Jan 11, 2022
-
Jan 5, 2022
PCI Biotech and MDimune announce research collaboration agreement
Jan 5, 2022
-
2021
-
Dec 14, 2021
PCI Biotech to present at DNB Nordic Healthcare Conference 2021
Dec 14, 2021
-
Dec 13, 2021
PCI Biotech: Independent Data Monitoring Committee recommends continuation of two treatments in the RELEASE trial
Dec 13, 2021
-
Dec 7, 2021
PCI Biotech: Update on regulatory interactions for the RELEASE trial
Dec 7, 2021
-
Nov 30, 2021
PCI Biotech and Immunicum Announce an Extension to Their Research Collaboration to Explore Novel Cancer Vaccination Treatments
Nov 30, 2021
-
Nov 29, 2021
PCI Biotech to present at ABGSC Nordic Rare Disease Seminar
Nov 29, 2021
-
Nov 17, 2021
PCI Biotech Q3 2021 interim results
Nov 17, 2021
-
Nov 9, 2021
PCI Biotech: Invitation to Q3 2021 result presentation
Nov 9, 2021
-
Nov 9, 2021
PCI Biotech to present at the 9th International mRNA Health Conference
Nov 9, 2021
-
Nov 8, 2021
PCI Biotech: Presentation of fimaCHEM for bile duct cancer at IPA masterclass series
Nov 8, 2021
-
Sep 6, 2021
PCI Biotech: Employee share option scheme
Sep 6, 2021
-
Aug 31, 2021
Financial calendar for PCI Biotech Holding ASA
Aug 31, 2021
-
Aug 31, 2021
PCI Biotech first half-year 2021 interim results
Aug 31, 2021
-
Aug 23, 2021
PCI Biotech: Invitation to first half-year 2021 result presentation
Aug 23, 2021
-
May 31, 2021
PCI Biotech: US patent for the vaccine technology (fimaVACC) in combination with checkpoint inhibitors
May 31, 2021
-
May 28, 2021
PCI Biotech receives Orphan Drug Designation in South Korea for fimaporfin in the treatment of bile duct cancer
May 28, 2021
-
May 28, 2021
Minutes from Annual General Meeting 2021
May 28, 2021
-
May 11, 2021
PCI Biotech is seeking a Scientific Alliance and Business Development Manager
May 11, 2021
-
May 7, 2021
Notice of Annual General Meeting 2021
May 7, 2021
-
May 7, 2021
PCI Biotech first quarter 2021 interim results
May 7, 2021
-
May 5, 2021
OliX Pharmaceuticals and PCI Biotech announce a collaboration to combine OliX asiRNA and PCI Biotech fimaNAc technologies
May 5, 2021
-
Apr 30, 2021
PCI Biotech: First US patient enrolled in the fimaCHEM pivotal RELEASE study
Apr 30, 2021
-
Apr 30, 2021
PCI Biotech: Invitation to first quarter 2021 results presentation
Apr 30, 2021
-
Apr 21, 2021
PCI Biotech Holding ASA publishes the Annual Report 2020
Apr 21, 2021
-
Apr 6, 2021
PCI Biotech to present at European Biotech Investor Days 2021
Apr 6, 2021
-
Feb 24, 2021
PCI Biotech fourth quarter and preliminary full year 2020 results
Feb 24, 2021
-
Feb 18, 2021
PCI Biotech: Invitation to fourth quarter 2020 results presentation
Feb 18, 2021
-
Feb 10, 2021
PCI Biotech - release of the RNA Therapeutics Virtual Conference presentation
Feb 10, 2021
-
Jan 22, 2021
PCI Biotech to present at RNA Therapeutics Virtual Conference
Jan 22, 2021
-
2020
-
Nov 23, 2020
PCI Biotech: Successful Phase I fimaVACC vaccination proof of concept study to be published in Frontiers in Immunology
Nov 23, 2020
-
Nov 16, 2020
PCI Biotech: European patent for treatment of bile duct cancer with the fimaCHEM technology
Nov 16, 2020
-
Nov 11, 2020
PCI Biotech third quarter 2020 results
Nov 11, 2020
-
Nov 4, 2020
PCI Biotech: Invitation to third quarter 2020 results presentation
Nov 4, 2020
-
Oct 26, 2020
First patient enrolled in Asia in the fimaCHEM pivotal RELEASE study
Oct 26, 2020
-
Oct 21, 2020
PCI Biotech: Preclinical research collaboration with big pharma ended
Oct 21, 2020
-
Oct 6, 2020
Job Advertisement: Clinical Project Director
Oct 6, 2020
-
Oct 6, 2020
PCI Biotech: Employee share option scheme
Oct 6, 2020
-
Sep 8, 2020
PCI Biotech: Capital increase registered and listing of new shares
Sep 8, 2020
-
Sep 3, 2020
PCI Biotech: Exercise of employee share options, mandatory notification of trade and resolution to increase share capital
Sep 3, 2020
-
Sep 1, 2020
PCI Biotech announce a research collaboration with DCprime to explore novel cancer vaccination concepts
Sep 1, 2020
-
Aug 26, 2020
First half-year 2020 results
Aug 26, 2020
-
Aug 19, 2020
PCI Biotech: Invitation to second quarter and first half 2020 results presentation
Aug 19, 2020
-
Aug 19, 2020
PCI Biotech: Publication of case report series from the Phase I study in bile duct cancer
Aug 19, 2020
-
Jul 13, 2020
PCI Biotech: Update on the preclinical research collaboration agreement with AstraZeneca
Jul 13, 2020
-
May 27, 2020
Minutes from Annual General Meeting 2020
May 27, 2020
-
May 26, 2020
Disclosure of voting rights for Chairman of the Board
May 26, 2020
-
May 6, 2020
Notice of Annual General Meeting 2020
May 6, 2020
-
May 6, 2020
First quarter 2020 results
May 6, 2020
-
Mar 31, 2020
PCI Biotech appoints Dr Amir Snapir as Chief Medical Officer
Mar 31, 2020
-
Mar 26, 2020
PCI Biotech: US patent for the vaccine technology (fimaVACC) with a new important class of adjuvants
Mar 26, 2020
-
Mar 25, 2020
PCI Biotech: Update on operational implications of the corona pandemic
Mar 25, 2020
-
Feb 26, 2020
Fourth quarter and preliminary 2019 results
Feb 26, 2020
-
Feb 19, 2020
Invitation to fourth quarter and preliminary 2019 results presentation
Feb 19, 2020
-
Jan 21, 2020
PCI Biotech: US patent granted for the vaccine technology (fimaVACC) in combination with cytokines
Jan 21, 2020
-
2019
-
Dec 12, 2019
PCI Biotech to present Phase I fimaVACC results at ESMO Immuno-Oncology 2019
Dec 12, 2019
-
Nov 27, 2019
PCI Biotech: Third quarter 2019 results
Nov 27, 2019
-
Nov 26, 2019
PCI Biotech: Expansion of preclinical research collaboration agreement with AstraZeneca
Nov 26, 2019
-
Nov 19, 2019
PCI Biotech to present at Jefferies 2019 London Healthcare Conference
Nov 19, 2019
-
Nov 19, 2019
Invitation to third quarter 2019 results presentation
Nov 19, 2019
-
Nov 12, 2019
PCI Biotech to present at BIO-Europe 2019
Nov 12, 2019
-
Oct 28, 2019
PCI Biotech to present at World Vaccine Congress Europe
Oct 28, 2019
-
Oct 9, 2019
PCI Biotech is hiring a Chief Medical Officer and a Chief Business Officer
Oct 9, 2019
-
Sep 9, 2019
Capital increase registered and listing of new shares
Sep 9, 2019
-
Aug 30, 2019
Mandatory notification regarding trade of shares
Aug 30, 2019
-
Aug 28, 2019
Second quarter and first half 2019 results
Aug 28, 2019
-
Aug 20, 2019
Invitation to second quarter and first half 2019 results presentation
Aug 20, 2019
-
Jul 22, 2019
Extension of preclinical research collaboration agreement with a top-10 large pharma company
Jul 22, 2019
-
Jul 3, 2019
PCI Biotech to present at IPA World Congress
Jul 3, 2019
-
Jun 21, 2019
Employee share option scheme
Jun 21, 2019
-
May 29, 2019
Minutes from Annual General Meeting 2019
May 29, 2019
-
May 23, 2019
First patient enrolled in the fimaChem pivotal RELEASE study
May 23, 2019
-
May 8, 2019
Notice of Annual General Meeting 2019
May 8, 2019
-
May 8, 2019
First quarter 2019 results
May 8, 2019
-
May 3, 2019
Successful clinical translation of the fimaVACC technology
May 3, 2019
-
Apr 30, 2019
Invitation to first quarter 2019 result presentation
Apr 30, 2019
-
Apr 9, 2019
Annual Report 2018
Apr 9, 2019
-
Apr 8, 2019
Final confirmation of successful safety read-out in the Phase I Extension study
Apr 8, 2019
-
Feb 28, 2019
Resignation of Chief Business Development Officer
Feb 28, 2019
-
Feb 25, 2019
Capital increase registered and listing of new shares
Feb 25, 2019
-
Feb 20, 2019
Exercise of employee share options, mandatory notification of trade and resolution to increase share capital
Feb 20, 2019
-
Feb 13, 2019
Fourth quarter and preliminary 2018 results
Feb 13, 2019
-
Feb 6, 2019
PCI Biotech invites to a presentation of the company's fourth quarter and preliminary 2018 report
Feb 6, 2019
-
2018
-
Dec 20, 2018
Preliminary confirmation of safety read-out from the fimaChem Phase I extension study in bile duct cancer
Dec 20, 2018
-
Dec 18, 2018
Extension of preclinical research collaboration agreement with a top-10 large pharma company
Dec 18, 2018
-
Nov 13, 2018
Third quarter 2018 results
Nov 13, 2018
-
Nov 6, 2018
Invitation to third quarter 2018 presentation
Nov 6, 2018
-
Oct 24, 2018
Capital increase registered and listing of new shares
Oct 24, 2018
-
Oct 19, 2018
PCI Biotech to present Phase I dose escalation results at ESMO
Oct 19, 2018
-
Oct 10, 2018
Capital increase registered and listing of new shares
Oct 10, 2018
-
Oct 4, 2018
Final results of the rights issue
Oct 4, 2018
-
Oct 3, 2018
Last day of subscription period
Oct 3, 2018
-
Sep 28, 2018
Last day of trading in subscription rights Monday 1 October 2018
Sep 28, 2018
-
Sep 20, 2018
Mandatory notification regarding exercise and trade of subscription rights
Sep 20, 2018
-
Sep 20, 2018
Mandatory notification regarding exercise and trade of subscription rights
Sep 20, 2018
-
Sep 20, 2018
Commencement of subscription period
Sep 20, 2018
-
Sep 17, 2018
Prospectus approved
Sep 17, 2018
-
Sep 14, 2018
Rights issue approved by the extraordinary general meeting
Sep 14, 2018
-
Aug 30, 2018
Second quarter and first half-year 2018 results
Aug 30, 2018
-
Aug 24, 2018
Key information relating to the preferential rights issue to be carried out by PCI Biotech Holding ASA
Aug 24, 2018
-
Aug 24, 2018
Notice of Extraordinary General Meeting
Aug 24, 2018
-
Aug 24, 2018
PCI Biotech convenes an extraordinary general meeting to propose a fully underwritten Rights Issue of NOK 360 million
Aug 24, 2018
-
Aug 23, 2018
Invitation to first half year 2018 presentation
Aug 23, 2018
-
Aug 20, 2018
PCI Biotech initiates research collaboration with Bavarian Nordic
Aug 20, 2018
-
Jul 10, 2018
Financial calendar for PCI Biotech Holding ASA
Jul 10, 2018
-
Jun 15, 2018
Extension of preclinical research collaboration agreement with a top-10 large pharma company
Jun 15, 2018
-
May 29, 2018
Minutes from Annual General Meeting 2018
May 29, 2018
-
May 28, 2018
Disclosure of voting rights for Chairman of the Board
May 28, 2018
-
May 24, 2018
PCI Biotech initiates research collaboration with IMV Inc
May 24, 2018
-
May 15, 2018
PCI Biotech to present at BioEquity Europe
May 15, 2018
-
May 8, 2018
Notice of Annual General Meeting 2018
May 8, 2018
-
May 8, 2018
First quarter 2018 report and presentation
May 8, 2018
-
May 2, 2018
Invitation to first quarter 2018 presentation
May 2, 2018
-
Apr 27, 2018
PCI Biotech Holding ASA will be transferred to Oslo Børs from 27.04.2018
Apr 27, 2018
-
Apr 25, 2018
Publication of prospectus summary for transfer of listing to Oslo Børs
Apr 25, 2018
-
Apr 17, 2018
Capital increase registered and listing of new shares
Apr 17, 2018
-
Apr 12, 2018
Exercise of employee share options and resolution to increase the share capital
Apr 12, 2018
-
Mar 20, 2018
PCI Biotech: Full year 2017 report – a transformative year
Mar 20, 2018
-
Mar 19, 2018
Annual Report 2017
Mar 19, 2018
-
Mar 13, 2018
Invitation to full year 2017 presentation
Mar 13, 2018
-
Mar 12, 2018
PCI Biotech to present at Bio-Europe Spring 2018
Mar 12, 2018
-
Jan 18, 2018
Extension of preclinical research collaboration agreement with a top-10 large pharma company
Jan 18, 2018
-
Jan 8, 2018
PCI Biotech to present at Biotech Showcase 2018
Jan 8, 2018
-
2017
-
Dec 20, 2017
PCI Biotech announces preliminary outcome of meetings with EMA and FDA for development of fimaporfin in inoperable cholangiocarcinoma
Dec 20, 2017
-
Nov 28, 2017
Third quarter 2017 report and presentation
Nov 28, 2017
-
Nov 21, 2017
Invitation to third quarter 2017 presentation
Nov 21, 2017
-
Nov 9, 2017
Board of Directors update
Nov 9, 2017
-
Nov 6, 2017
PCI Biotech to present at BIO-Europe 2017
Nov 6, 2017
-
Oct 17, 2017
Employee share option scheme
Oct 17, 2017
-
Oct 5, 2017
PCI Biotech receives US Orphan Drug Designation for fimaporfin in the treatment of bile duct cancer (cholangiocarcinoma)
Oct 5, 2017
-
Sep 12, 2017
Initial clinical results from Phase I indicate that vaccination with fimaVacc enhances cellular immune responses
Sep 12, 2017
-
Sep 8, 2017
Capital increase registered and listing of new shares
Sep 8, 2017
-
Sep 6, 2017
Exercise of employee share options, mandatory notification of trade and resolution to increase the share capital
Sep 6, 2017
-
Aug 29, 2017
First half year 2017 report and presentation
Aug 29, 2017
-
Aug 23, 2017
PCI Biotech appoints Dr Hans Olivecrona as Chief Medical Officer
Aug 23, 2017
-
Aug 22, 2017
Invitation to first half year 2017 presentation
Aug 22, 2017
-
Aug 11, 2017
First patient dosed in the fimaCHEM Phase I extension study
Aug 11, 2017
-
Jul 10, 2017
Extension of preclinical research collaboration agreement with a top-10 large pharma company
Jul 10, 2017
-
Jul 5, 2017
Interview about fimaCHEM at the Medica Trade Fair homepage 2017
Jul 5, 2017
-
May 29, 2017
Minutes from Annual General Meeting 2017
May 29, 2017
-
May 23, 2017
PCI Biotech presenting at Bio€quity Europe
May 23, 2017
-
May 22, 2017
PCI Biotech and RXi Pharmaceuticals Extend Research Collaboration to the Field of Immuno-oncology
May 22, 2017
-
May 18, 2017
PCI Biotech to present at Bio€quity Europe
May 18, 2017
-
May 16, 2017
First quarter 2017 report and presentation
May 16, 2017
-
May 8, 2017
Notice of Annual General Meeting 2017
May 8, 2017
-
May 5, 2017
Invitation to first quarter 2017 presentation
May 5, 2017
-
May 5, 2017
Employee share option scheme
May 5, 2017
-
Apr 25, 2017
Annual Report 2016
Apr 25, 2017
-
Apr 21, 2017
Presentation of fimaCHEM Phase I data in bile duct cancer at The International Liver Congress 2017
Apr 21, 2017
-
Apr 7, 2017
PCI Biotech searching for Chief Medical Officer
Apr 7, 2017
-
Apr 6, 2017
PCI Biotech to present clinical data on its phase I/II trial in bile duct cancer at The International Liver Congress 2017
Apr 6, 2017
-
Mar 28, 2017
PCI Biotech to present at 5th Cancer BioPartnering & Investment Forum
Mar 28, 2017
-
Mar 22, 2017
PCI Biotech to present at Bio-Europe Spring 2017
Mar 22, 2017
-
Mar 21, 2017
PCI Biotech to present poster at 4th Immunotherapy of cancer conference
Mar 21, 2017
-
Feb 28, 2017
Fourth quarter and preliminary 2016 report and presentation
Feb 28, 2017
-
Feb 20, 2017
Invitation to fourth quarter 2016 presentation
Feb 20, 2017
-
Jan 27, 2017
PCI Biotech awarded NOK 13.8 million from The Research Council of Norway to further development of PCI for use in vaccination
Jan 27, 2017
-
Jan 19, 2017
Capital increase registered and listing of new shares
Jan 19, 2017
-
Jan 10, 2017
Final results of the rights issue
Jan 10, 2017
-
Jan 10, 2017
PCI Biotech presentation from Biotech Showcase 2017
Jan 10, 2017
-
Jan 6, 2017
The PCI Biotech and Ultimovacs collaboration awarded NOK 500,000 from Innovation Norway
Jan 6, 2017
-
Jan 6, 2017
PCIB – preliminary results of the rights issue
Jan 6, 2017
-
Jan 6, 2017
PCI Biotech to present at Biotech Showcase 2017
Jan 6, 2017
-
2016
-
Dec 21, 2016
Mandatory notification regarding exercise and trade of subscription rights and trade of shares
Dec 21, 2016
-
Dec 14, 2016
Successful Investigational New Drug (IND) application
Dec 14, 2016
-
Dec 14, 2016
Commencement of subscription period
Dec 14, 2016
-
Dec 13, 2016
Update on the existing pre-clinical research collaboration agreement with a top-10 large pharma company
Dec 13, 2016
-
Dec 8, 2016
PCI Biotech and eTheRNA immunotherapies initiate research collaboration
Dec 8, 2016
-
Dec 8, 2016
Rights issue approved by the extraordinary general meeting
Dec 8, 2016
-
Nov 22, 2016
Third quarter 2016 results
Nov 22, 2016
-
Nov 17, 2016
Notice to the extraordinary general meeting to resolve a fully underwritten Rights Issue of NOK 70 million
Nov 17, 2016
-
Nov 17, 2016
PCI Biotech convenes an extraordinary general meeting to propose a fully underwritten Rights Issue of NOK 70 million
Nov 17, 2016
-
Nov 10, 2016
Distribution of today’s presentation
Nov 10, 2016
-
Nov 8, 2016
PCI Biotech to present at BIO-Europe 2016
Nov 8, 2016
-
Nov 4, 2016
PCI Biotech to present poster at the ESMO Symposium on Immuno-Oncology 2016
Nov 4, 2016
-
Nov 2, 2016
Invitation to in-depth company update
Nov 2, 2016
-
Oct 27, 2016
Update on funding of further development
Oct 27, 2016
-
Oct 17, 2016
Results from the bile duct cancer study will be presented as late-breaking news at United European Gastroenterology Week
Oct 17, 2016
-
Sep 23, 2016
PCI Biotech to present poster at the Second International Cancer Immunotherapy Conference
Sep 23, 2016
-
Sep 13, 2016
PCI Biotech to present phase I results at Nordic Life Science Days 2016
Sep 13, 2016
-
Sep 6, 2016
Independent evaluation confirms early promising signs of efficacy in the phase I/II bile duct cancer study
Sep 6, 2016
-
Sep 5, 2016
First subject dosed in the fimaVACC phase I study
Sep 5, 2016
-
Sep 1, 2016
PCI Biotech and BioNTech initiates preclinical research collaboration
Sep 1, 2016
-
Aug 30, 2016
Second quarter and first half year 2016 results
Aug 30, 2016
-
Aug 29, 2016
PCI Biotech granted Orphan Drug Designation of fimaporfin for treatment of cholangiocarcinoma in EU
Aug 29, 2016
-
Aug 24, 2016
Invitation to second quarter and first half year 2016 presentation
Aug 24, 2016
-
Jul 28, 2016
Publication of the fimaporfin (Amphinex) first-in-man Phase I study in Lancet Oncology
Jul 28, 2016
-
Jul 26, 2016
PCI Biotech receives positive opinion for Orphan Drug Designation of fimaporfin for treatment of cholangiocarcinoma in EU
Jul 26, 2016
-
Jul 1, 2016
Curida and PCI Biotech have entered into a manufacturing agreement
Jul 1, 2016
-
May 26, 2016
Pre-clinical research collaboration agreement with top-10 large pharma company extended
May 26, 2016
-
May 19, 2016
Minutes from Annual General Meeting 2016
May 19, 2016
-
May 18, 2016
PCI Biotech to present at Anglonordic Life Science Conference 2016
May 18, 2016
-
May 10, 2016
PCI Biotech to present at BioEquity Europe 2016
May 10, 2016
-
May 9, 2016
PCI Biotech to present poster at CIMT Annual Meeting 2016
May 9, 2016
-
May 4, 2016
PCI Biotech: Mandatory notification of trade
May 4, 2016
-
May 3, 2016
PCI Biotech: First quarter 2016 report
May 3, 2016
-
Apr 26, 2016
Notice of Annual General Meeting 2016
Apr 26, 2016
-
Apr 26, 2016
PCI Biotech to present at BIOTrinity 2016
Apr 26, 2016
-
Apr 11, 2016
Annual Report 2015
Apr 11, 2016
-
Apr 5, 2016
PCI Biotech to present at BIO-Europe Spring 2016
Apr 5, 2016
-
Feb 9, 2016
PCI Biotech: Fourth quarter and preliminary full year 2015 results
Feb 9, 2016
-
Jan 27, 2016
PCI Biotech and Ultimovacs initiates preclinical research collaboration
Jan 27, 2016
-
Jan 22, 2016
Dose escalation in the bile duct cancer study completed with promising early signs of efficacy
Jan 22, 2016
-
2015
-
Dec 15, 2015
PCI Biotech to present at DNB Health Care Conference 2015
Dec 15, 2015
-
Nov 30, 2015
Mandatory notification of trade - employee share option scheme
Nov 30, 2015
-
Nov 17, 2015
PCI Biotech 3rd Quarter report
Nov 17, 2015
-
Nov 4, 2015
PCI Biotech to present at BIO-Europe
Nov 4, 2015
-
Oct 21, 2015
PCI Biotech to present at the 14th Annual BIO Investor Forum
Oct 21, 2015
-
Oct 16, 2015
PCI Biotech strengthens the organisation by appointing world leading experts to inaugural Scientific Advisory Committee
Oct 16, 2015
-
Oct 13, 2015
PCI Biotech to present at the Oligonucleotide Therapeutics Society (OTS) 11th Annual Meeting
Oct 13, 2015
-
Sep 18, 2015
Presentation of PCI Biotech’s bile duct study at the annual German Gastroenterology Congress 2015
Sep 18, 2015
-
Sep 10, 2015
PCI Biotech signs pre-clinical research collaboration agreement with a top-10 large pharma company
Sep 10, 2015
-
Aug 31, 2015
PCI Biotech announces activation of Oslo University Hospital as a new clinical site
Aug 31, 2015
-
Aug 18, 2015
Second quarter and first half year 2015 results
Aug 18, 2015
-
Aug 18, 2015
Successful completion of the third dose cohort in the study for patients with inoperable bile duct cancer
Aug 18, 2015
-
Aug 6, 2015
PCI Biotech: Presentation of second quarter and first-half year 2015 results
Aug 6, 2015
-
Jul 13, 2015
Open position as Director Clinical Science / Medical Director
Jul 13, 2015
-
Jul 6, 2015
Mandatory notification of trade
Jul 6, 2015
-
Jun 8, 2015
Mandatory notification of trade
Jun 8, 2015
-
Jun 3, 2015
Update on the ENHANCE study
Jun 3, 2015
-
May 12, 2015
PCI Biotech: Minutes from Annual General Meeting 2015
May 12, 2015
-
May 12, 2015
PCI Biotech will be presenting at BioTrinity 2015, Novotel London West, May 11-13, 2015
May 12, 2015
-
May 12, 2015
PCI Biotech: First quarter 2015 Report
May 12, 2015
-
May 7, 2015
Mandatory notification of trade
May 7, 2015
-
Apr 28, 2015
Capital increase registered and listing of new shares
Apr 28, 2015
-
Apr 27, 2015
Mandatory notification of trade - exercise of employee share options
Apr 27, 2015
-
Apr 20, 2015
Notice of Annual General Meeting 2015
Apr 20, 2015
-
Apr 20, 2015
Mandatory notification of trade - Share option program
Apr 20, 2015
-
Apr 8, 2015
PCI Biotech to present at the World Vaccine Congress 2015
Apr 8, 2015
-
Apr 7, 2015
PCI Biotech initiates pre-clinical research collaboration in siRNA therapeutics
Apr 7, 2015
-
Mar 24, 2015
Annual Report 2014
Mar 24, 2015
-
Mar 6, 2015
PCI Biotech announces positive feedback regarding a patent application in vaccination and immunotherapy
Mar 6, 2015
-
Feb 24, 2015
Fourth quarter and preliminary full year 2014 results
Feb 24, 2015
-
Feb 20, 2015
Completion of the third group in the intra-tumour light dose escalation part of the ENHANCE study
Feb 20, 2015
-
Feb 6, 2015
Successful completion of the second dose cohort in the study for patients with inoperable bile duct cancer
Feb 6, 2015
-
Feb 4, 2015
Preliminary results of the rights issue
Feb 4, 2015
-
Jan 27, 2015
PCI Biotech to present at Immunotherapy Forum 2015
Jan 27, 2015
-
Jan 20, 2015
PCI Biotech: Successful Investigational New Drug application (IND) review for Amphinex
Jan 20, 2015
-
Jan 20, 2015
Fully underwritten rights issue of NOK 70 million - link to prospectus and online subscription
Jan 20, 2015
-
Jan 13, 2015
PCI Biotech to present at Biotech Showcase™ 2015
Jan 13, 2015
-
Jan 7, 2015
Ex subscription rights today
Jan 7, 2015
-
Jan 6, 2015
Rights issue approved by the extraordinary general meeting
Jan 6, 2015
-
2014
-
Dec 9, 2014
Publication of results showing that the PCI technology can significantly improve vaccination treatment in a melanoma model
Dec 9, 2014
-
Dec 9, 2014
PCI Biotech convenes an extraordinary general meeting to propose a fully underwritten Rights Issue of NOK 70 million
Dec 9, 2014
-
Nov 18, 2014
Third quarter 2014 results
Nov 18, 2014
-
Nov 13, 2014
PCI Biotech presenting at DNB Markets Health Care Conference 2014
Nov 13, 2014
-
Oct 14, 2014
PCI Biotech presented at the World Vaccine Congress Europe 2014
Oct 14, 2014
-
Sep 30, 2014
PCI Biotech to present at SACHS Associates 14th Annual Biotech in Europe Forum
Sep 30, 2014
-
Aug 26, 2014
Second quarter and first half year 2014 results
Aug 26, 2014
-
Aug 22, 2014
Successful completion of the second group in the intra-tumour light dose escalation part of the ENHANCE study
Aug 22, 2014
-
Aug 20, 2014
Presentation of second quarter and first half year 2014 results
Aug 20, 2014
-
Jun 20, 2014
PCI Biotech to present at The 2014 BIO International Convention, San Diego
Jun 20, 2014
-
Jun 20, 2014
Annual General Meeting 2014
Jun 20, 2014
-
May 12, 2014
PCI Biotech to present at BioTrinity 2014
May 12, 2014
-
May 7, 2014
Successful completion of the first dose cohort in the study for patients with inoperable bile duct cancer
May 7, 2014
-
Feb 4, 2014
First patient treated in the study of Amphinex in patients with bile duct cancer (Cholangiocarcinoma)
Feb 4, 2014
-
Jan 30, 2014
PCI Biotech awarded NOK 12.5 million from The Research Council of Norway to further development of PCI for use in vaccination
Jan 30, 2014
-
Jan 24, 2014
Successful completion of the first group in the intra-tumour light dose escalation part of the ENHANCE study
Jan 24, 2014
-
2013
-
2012
-
2011
-
2010
-
2009
-
Dec 3, 2009
Initiated pre-clinical trials for the use of PCI in the treatment of Bladder Cancer
Dec 3, 2009
-
Oct 19, 2009
Successful completion of the first dose group in the Phase I/II study of Amphinex® in cancer patients
Oct 19, 2009
-
Aug 24, 2009
First cancer patient included in PCI Biotech's Phase I/II trial of Amphinex®
Aug 24, 2009
-
Aug 21, 2009
Anti-tumour drug more potent with light-directed delivery
Aug 21, 2009
-
Jul 14, 2009
Light-directed drug delivery system slows growth of invasive tumours
Jul 14, 2009
-
Jun 28, 2009
Allotted Share Options
Jun 28, 2009
-
May 28, 2009
Light-direction shows promise for siRNA therapeutics targeting
May 28, 2009
-
May 4, 2009
General meeting held April 2009
May 4, 2009
-
Apr 30, 2009
LumiSource - novel light source for 'in vitro' research
Apr 30, 2009
-
Mar 23, 2009
PCI Biotech-led consortium awarded EUR 1.1 million grant from the EU Eurostars Programme
Mar 23, 2009
